Natural killer (NK) cells, which represent a small fraction of normal peripheral blood mononuclear cells, were purified by immunofluorescent cell sorting of NKH1+ cells. cytotoxicity of NKH1+ cells could be enhanced through activation by monoclonal antibodies (anti-T11(2) and anti-T11(3)) specific for epitopes of the sheep erythrocyte receptor or by recombinant interleukin-2 (rIL-2). After 18 h, incubation with both anti-T11(2/3) and rIL-2 resulted in similar levels of enhanced cytotoxicity against NK-resistant as well as NKsensitive targets. Before and after induction, cytotoxicity was found predominantly within the NKH1+ population. These results suggest that several distinct mechanisms may be capable of enhancing NK activity and that the cells responsible for lymphokine-activated killing are likely to be the same population capable of spontaneous or natural killing before activation in vitro. Abstract Natural killer (NK) cells, which represent a small fraction of normal peripheral blood mononuclear cells, were purified by immunofluorescent cell sorting of NKH1+ cells. Cytotoxicity of NKH1+ cells could be enhanced through activation by monoclonal antibodies (anti-T112 and anti-Ti13) specific for epitopes of the sheep erythrocyte receptor or by recombinant interleukin-2 (rIL-2). After 18 h, incubation with both anti-T112/3 and rIL-2 resulted in similar levels of enhanced cytotoxicity against NK-resistant as well as NK-sensitive targets. Before and after induction, cytotoxicity was found predominantly within the NKH1+ population. These results suggest that several distinct mechanisms may be capable of enhancing NK activity and that the cells responsible for lymphokine-activated killing are likely to be the same population capable of spontaneous or natural killing before activation in vitro.
Introduction
Natural killer (NK)' cells have been operationally defined as a population of lymphocytes capable of mediating direct cytotoxicity against a variety oftarget cells without prior immunization (1) . Although NK cells in peripheral blood have been shown to be phenotypically and functionally heterogeneous (2), they appear morphologically as a relatively homogeneous population of large granular lymphocytes. Moreover, there are some NKassociated antigens that appear to be expressed on all NK cells and only rarely on other cell types. One ofthese antigens, termed NKH 1, is a 200-Kd structure that is only expressed on 10-12% of peripheral blood mononuclear cells (PBMC) (3) . NKH1 ' cells appear morphologically as LGL. All (5) . By using a combination of both anti-Tl 12 and anti-Tl 13 monoclonal antibodies, it is possible to activate T 1 + cells in vitro and induce expression of surface receptors for IL-2. Activation through the Tl 1 structure is independent of expression of T cell receptor for antigen and has been found to occur with immature thymocytes (6) as well as T3-negative NK clones (7) . In addition, it has been demonstrated that cellular activation with anti-Tl 1 monoclonal antibodies induces unrestricted killing by cytolytic T cell clones as well as cytotoxicity of NK clones against otherwise resistant targets (8) . In the present studies, we demonstrate that the cytolytic function, of peripheral blood NK cells can be markedly enhanced through activation of the CD2 and that this enhancement is comparable to that observed following IL-2 activation (9).
Methods
Monoclonal antibodies. The antibodies used in these studies have been previously described in detail. Anti-NKHIA is an IgM monoclonal antibody with identical specificity to anti-NKH1 (N901) (3). Anti-T 112 and anti-TI 13 define two different epitopes of the E rosette receptor (5) . 2F12 is a monoclonal antibody recognizing the alpha chain of LFA-l (10).
Cell lines. Molt4 is a T cell leukemic line. K562 is a cell line established from a patient with myelogenous leukemia. OH-I is a small lung cell carcinoma line provided by Dr. S. Bernal (1 1) . SKRC is derived from a renal carcinoma and referred elsewhere as SKRC-1 (12) . Mewo is a melanoma cell line (13 Cytotoxicity assays. Cytotoxicity assays were performed according to a standard 5"Cr release method previously described (3). After cell sorter purification, fractionated cells were incubated with either recombinant interleukin-2 (rIL-2) medium (1,000 U/ml; Biogen S. A., Geneva, Switzerland) or anti-T1 12 and anti-T1 13 media (1/250 final dilution of ascites) in microtiter plates for 18 h at 37°C before adding 5"Cr-labeled target cells. All reagents were subsequently left in the wells throughout the 4-h cytotoxicity assay. 18-h incubation with anti-T 11 antibodies was found to be optimal for induction of cytotoxicity. Longer incubations with these reagents resulted in less enhancement. In contrast, rIL-2-induced cytotoxicity was clearly evident at 18 h but in some instances was not maximal until after 48 h of incubation. All experiments were done in triplicate using V bottom microtiter plates. Medium was RPM 1 1640 plus 5% pooled human AB serum containing 50 U/ml penicillin and 50 Ag/ml streptomycin. Assays were performed at various effector/ target (E/T) ratios using between 3,000 and 5,000 targets cells per well.
With all targets used, the minimum release (targets incubated in media alone) was <20% ofthe maximum release (targets incubated in 1% Triton-X detergent Fig. 1 A) all of the natural cytotoxicity against a standard NK target cell, K562, is contained within the NKH1 + population. After 18-h incubation with rIL-2 ( Fig. 1 B) , the NK activity of unseparated PBMC is significantly enhanced and cytotoxicity remains confined to the NKH1+ subset. Results shown in Fig. 1 Effect ofanti-LFA-J antibody on induced cytotoxicity. The LFA-I antigen has been shown previously to play an important role in the cell-cell interactions and formation of conjugates that occur during the cytolytic process ofNK and other cytolytic cells (14) . To characterize the role ofLFA-I-mediated cell adhesion during Ti 1-induced cytotoxicity, we added monoclonal 2FI2 antibody to cells during activation before cytotoxicity assays. As shown in Fig. 2 B, Ti 1-mediated enhancement of cytotoxicity can be induced against additional NK target cells such as Molt4 resulting in more than a two-fold increase in cytotoxic activity after 18 h incubation at 37°C. As seen previously with other target cells, cytotoxicity is contained within the NKH1+ fraction; very little killing can be found in the NKH 1 fraction either before or after T 11 activation. When 2F12 monoclonal antibody is added to the NK assay (Fig. 2 D) , cytotoxicity of TiI-induced cells is reduced by >50% and is similar to that observed before activation. These results suggest that the Tl 1-induced enhancement of cytotoxicity is at least in part due to an increased binding of effectors to target cells, mediated through LFA-I antigen. Similar results were obtained with 2F12 antibody and rIL-2-activated NK cells (data not shown).
Induction of cytotoxicity against resistant targets. To test whether TI 1 activation would induce cytotoxicity against NKresistant tumor cells, we performed similar experiments with three different solid tumor cell lines as targets. As shown in Fig.  3 , the melanoma cell line Mewo and the renal cell carcinoma line SKRC are not killed by peripheral blood lymphocytes (PBL) incubated in media only. PBL are able to exhibit minimal killing (7%) against the small-cell lung carcinoma line OH-1. After activation by anti-Tl 12/3, PBL exert significantly more cytotoxicity against each of the three lines (14%, 14%, and 17%, respectively).
Comparing the cytotoxic activity ofNKHI+ and NKHI-sorted cells after incubation in media only, we observed that NKH 1 + cells are able to mediate a low level of killing against OH-I cells (14% cytotoxicity) but very little cytotoxicity (<6%) against Mewo and SKRC targets. NKHI -cells are not able to kill any of these targets. After T1 12/3 activation, cytotoxicity of NKHI+ cells is enhanced against all three targets, but NKHI -effectors have very little activity (always <6%). Similar induction of cytotoxicity within the NKH1I population was observed following activation ofeffector cells with rIL-2. This data therefore supports the hypothesis that NKH1' cells are responsible for both rIL-2 and T 1 -induced killing of NK-resistant targets by PBL.
Discussion
In summary, this study demonstrates that the cytotoxic function ofpurified NKHlI peripheral blood NK cells can be significantly enhanced via the CD2 pathway. The extent of NK enhancement after an 18-h incubation period is quite similar to the effects seen after rIL-2 activation. Moreover, our data indicate that ac- (20) . Taken together, these studies support the view that the LAK phenomenon primarily reflects the functional effects of various lymphokines in the regulation of NK activity in vivo.
